Effects of Obstructive Sleep Apnea and Obesity on Morphine Pharmacokinetics in Children

• Published in: Anesthesia and analgesia Vol. 131; no. 3; pp. 876 - 884
• Main Authors: Dalesio, Nicholas M., Lee, Carlton K. K., Hendrix, Craig W., Kerns, Nikole, Hsu, Aaron, Clarke, William, Collaco, Joseph M., McGrath-Morrow, Sharon, Yaster, Myron, Brown, Robert H., Schwartz, Alan R.
• Format: Journal Article
• Language: English
• Published: United States Lippincott Williams & Wilkin 01-09-2020; International Anesthesia Research Society
• Subjects: Age Factors; Analgesics, Opioid - administration & dosage; Analgesics, Opioid - blood; Analgesics, Opioid - pharmacokinetics; Biomarkers - blood; Biotransformation; Child; Child, Preschool; Drug Dosage Calculations; Female; Humans; Leptin - blood; Male; Models, Biological; Morphine - administration & dosage; Morphine - blood; Morphine - pharmacokinetics; Pediatric Obesity - blood; Pediatric Obesity - complications; Pediatric Obesity - diagnosis; Sleep Apnea, Obstructive - blood; Sleep Apnea, Obstructive - complications; Sleep Apnea, Obstructive - diagnosis; Surgical Procedures, Operative
• ISSN: 0003-2999; 1526-7598
• DOI: 10.1213/ANE.0000000000004509

BACKGROUND:Obesity increases susceptibility to chronic pain, increases metabolism, and is associated with obstructive sleep apnea syndrome (OSAS), all which can complicate perioperative pain management of patients. In addition, obesity and OSAS can cause elevation of the adipose-derived hormone leptin, which increases metabolism. We hypothesized that obesity along with sleep apnea and leptin independently enhance morphine pharmacokinetics.
METHODS:Children 5–12 years of age who were presenting for surgery were administered a morphine dose of 0.05 mg/kg. Blood was collected at baseline and at subsequent preset times for pharmacokinetic analysis of morphine and its metabolites. Three groups were studieda nonobese group with severe OSAS, an obese group with severe OSAS, and a control group.
RESULTS:Thirty-four patients consisting of controls (n = 16), nonobese/OSAS (n = 8), and obese/OSAS (n = 10) underwent analysis. The obese/OSAS group had a higher dose-adjusted mean maximum morphine concentration (CMAX) over 540 minutes compared to the controls (P < .001) and those with only OSAS (P = .014). The obese/OSAS group also had lower volume of distribution (Vd) when compared to OSAS-only patients (P = .007). In addition, those in the obese/OSAS group had a higher morphine 3-glucuronide (M3G) maximum concentration (P = .012) and a higher ratio of M3G to morphine than did the control group (P = .011). Time to maximum morphine 6-glucuronide (M6G) concentration was significantly lower in both nonobese/OSAS and obese/OSAS groups than in the control group (P < .005). C-reactive protein (CRP), interleukin (IL)-10, and leptin were all higher in the obese/OSAS group than in controls (P = .004, 0.026, and <0.001, respectively), and compared to OSAS-only patients, CRP (P = .013) and leptin (P = .002) levels were higher in the obese/OSAS group.
CONCLUSIONS:The combination of obesity and OSAS was associated with an increase in morphine metabolism compared with that in normal-weight controls. Our previous study in mice demonstrated that obesity from leptin deficiency decreased morphine metabolism, but that metabolism normalized after leptin replacement. Leptin may be a cause of the increased morphine metabolism observed in obese patients.